Contact
/
Home
/
About
Team
Portfolio
Exit History
News
About
Team
Portfolio
Exit History
News
Advent Life Sciences
Advent Life Sciences
Page 1 of 25
<< Start
< Prev
1
2
3
4
5
6
7
8
9
10
Next >
End >>
04.08.2022
F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofim
Press Release
04.08.2022
GILEAD SCIENCES TO ACQUIRE MIROBIO
Press Release
01.07.2022
Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
Press Release
28.06.2022
Wondr Medical raise £12 million in Seed round to accelerate global collaboration across the medical community
Press Release
14.06.2022
PROXIMIE RAISES $80 MILLION IN SERIES C FUNDING TO ACCELERATE PRODUCT EXPANSION OF FULL-SERVICE CONNECTED SURGICAL PLATFORM
Press Release
26.05.2022
Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting
Press Release
25.05.2022
Advent Life Sciences Announces Growth of Investment Team with Three Senior Appointments
Press Release
16.05.2022
Shionogi & Co., Ltd. and F2G Ltd., Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia
Press Release
11.05.2022
Artax Biopharma Closes Financing to Advance Clinical Stage First-in- Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Press Release
04.05.2022
Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics
Press Release
©2022 Advent Life Sciences